holesale Price 5mg 10mg 15mg Retatrutide Weight Loss CAS: 2381089 83 2
26 Inquiries
2460055-10-9
Electronic Grade
99.9%
Shanjghai,Chian
hzy
10pcs/box
2026-06-27
Peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceFOXO4-DRI (Retro-Inverso) is a synthetic, slightly modified version of the standard FOXO4 protein. The modification prolongs half-life of the protein and allows it to interfere with normal FOXO4 function. FOXO4-DRI has been shown in research to prevent normal FOXO4 binding to p53, thereby allowing for elimination of senescent cells, improved organ function, and younger tissue “biological age.” FOXO4-DRI impacts insulin signaling, cell cycle regulation, and oxidative stress signaling pathways. FOXO4-DRI is a cell penetrating peptide shown to selectively induce apoptosis of senescent cells thereby reversing effects of aging in animal studies.Basic Info
-
Product Name:
FOXO4-DRI
Other Name:FOXO4-DRI;FOXO4 /FOXO4-DRI;FOX04-DRI (D-Retro-Inverso);Fox4-dri
CAS No.:2460055-10-9
Molecular Weight:0
Color/Form:White to off-white
Categories:
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptide
-
Location:
Room 1501, Building 1, Changnan Mansion, Country Garden, on the west side of Taoyang North Road
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
11
-
Year of Establishment:
2025
-
-
Inquiry History26 Inquiries
Country Product Purchase Quantity Date Posted 
United States
FOXO4-DRI
1 G Dec 3, 2023
United States
Fox04-dri
1 G May 20, 2026
United States
hot-sale-high-purity-raw-powder-fox04-dri-nad-ghk-cu-mot
2 PCS Dec 19, 2025
United States
foxo4 dri
10 MT Dec 13, 2025
United States
Fox04
10 MG Oct 30, 2024 
United Kingdom
High purity foxo4
1 G May 31, 2026
United Kingdom
Foxo4-Dri
10 MG May 5, 2026
United States
Fox04-dri
100 MG Apr 28, 2026 
Cyprus
Foxo4 dri
10 MT Apr 4, 2026
Cyprus
FOXO4-DRI
1 KG Feb 2, 2026
United States
FOX04-DRI
10 PCS Jan 12, 2026
United States
FOX04
10 PCS Jan 12, 2026
United States
Foxo4 Dri
40 MG Sep 15, 2025
United States
Fox04 dri
10 MT Jun 21, 2026
United States
FOX04-DRI powder
10 MT May 29, 2026
United States
fox04
1 G Apr 29, 2026
United States
FOXO4-DRI
1 KG Mar 23, 2026
United States
Foxo4-Dri
2 Nov 24, 2025
United States
FOXO4
10 PCS Nov 15, 2025
United States
Fox04
1 G Nov 10, 2025 Post an enquiry for this product
